A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

Phase 2
Not yet recruiting
Conditions
Interventions
Registration Number
NCT06717425
Lead Sponsor
Pfizer
Brief Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). ...

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
252
Inclusion Criteria
  • Male or non-pregnant, non-breastfeeding female, 18 to 74 years of age at Visit 1
  • Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as <5 kg change in the 12 weeks before Visit 1
  • Eligible and willing to receive required background medicine
  • Willing and able to comply with all study procedures

Key

Read More
Exclusion Criteria
  • Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes.
  • Use of any prohibited prior or concomitant medication(s)
  • Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PF-07976016 Dose 1PF-07976016-
PF-07976016 Dose 2PF-07976016-
PF-07976016 Dose 3PF-07976016-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Percent change from baseline in body weightBaseline to Week 16
Secondary Outcome Measures
NameTimeMethod
Number of participants with treatment emergent adverse eventsFrom first dose (Day 1) up to 28-35 days after final dose, a total of approximately 21 weeks
© Copyright 2024. All Rights Reserved by MedPath